Francesco Galimi, MD, PhD
Francesco Galimi, MD PhD is Executive Medical Director and General Manager, Early Development at Amgen, where he is responsible for the company’s early myeloma pipeline.
Dr. Galimi began his industry career at Amgen in 2004, and he held a number of positions in research, early development, and clinical development, most recently as Medical Director, Clinical Research. He then spent three years at Novartis, as Executive Medical Director, Oncology Translational Medicine, before joining Onyx in 2014 as Head of Clinical Development.
Dr. Galimi holds an MD, a PhD in molecular oncology, and a board certification in medical oncology from the University of Torino, Italy. He spent many years in academia before joining the industry, and he still holds an academic appointment in Italy as associate professor of histology and cell biology.